Carla Verri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3072715/publications.pdf

Version: 2024-02-01

28	1,839	516215 16	676716 22
papers	citations	h-index	g-index

28	28	28	3175
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3713-3718.	3.3	641
2	Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study. Journal of Clinical Oncology, 2014, 32, 768-773.	0.8	372
3	Plasma DNA Quantification in Lung Cancer Computed Tomography Screening. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 69-74.	2.5	96
4	Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell Death and Disease, 2014, 5, e1564-e1564.	2.7	73
5	Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget, 2015, 6, 32868-32877.	0.8	69
6	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clinical Cancer Research, 2019, 25, 2166-2173.	3.2	67
7	Fragile Histidine Triad Gene Inactivation in Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 396-401.	2.5	63
8	Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR. BMC Genomics, 2015, 16, 849.	1.2	62
9	YAP1acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. Oncotarget, 2014, 5, 2608-2621.	0.8	62
10	Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients. Molecules, 2014, 19, 3038-3054.	1.7	60
11	Circulating mirâ€320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. International Journal of Cancer, 2019, 144, 2746-2761.	2.3	56
12	Therapeutic Use of MicroRNAs in Lung Cancer. BioMed Research International, 2014, 2014, 1-8.	0.9	44
13	Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget, 2018, 9, 6346-6355.	0.8	39
14	Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. Expert Review of Molecular Diagnostics, 2015, 15, 801-813.	1.5	32
15	MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening. Journal of Visualized Experiments, 2017, , .	0.2	27
16	Elevated levels of the acuteâ€phase serum amyloid are associated with heightened lung cancer risk. Cancer, 2010, 116, 1326-1335.	2.0	21
17	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 2009, 34, 1477-1486.	3.1	15
18	Mutational Profile from Targeted NGS Predicts Survival in LDCT Screeningâ€"Detected Lung Cancers. Journal of Thoracic Oncology, 2017, 12, 922-931.	0.5	13

#	Article	IF	Citations
19	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer, 2019, 132, 17-23.	0.9	12
20	Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: A validation analysis. Lung Cancer, 2009, 66, 270-271.	0.9	7
21	MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature. Microarrays (Basel, Switzerland), 2016, 5, 18.	1.4	7
22	Abstract A19: Origin and functional role of plasma circulating miRNAs.. Clinical Cancer Research, 2014, 20, A19-A19.	3.2	1
23	Abstract 1162: MicroRNA expression profiles of tumors, normal lung tissues and plasma samples from spiral-computed tomography (CT) trial for early lung cancer detection. , 2011, , .		0
24	Abstract IA22: miRNA and lung cancer: Early detection in high-risk subjects. Clinical Cancer Research, 2012, 18, IA22-IA22.	3.2	0
25	Abstract 871: Clinical utility of a plasma microRNA biomarker within lung cancer screening. , 2014, , .		0
26	Abstract 932: A plasma microRNAs test predicts prognosis and disease status at follow-up in screening-detected lung cancer patients. , 2015, , .		0
27	Abstract 948: Microenvironmental origin of circulating miRNAs in lung cancer. , 2016, , .		0
28	Abstract 2753: Mutational profiles from targeted NGS combine with miRNA-based liquid biopsy to predict survival in LDCT screening-detected lung cancers. , 2017, , .		0